Literature DB >> 20833132

Increased transient receptor potential vanilloid type 1 (TRPV1) channel expression in hypertrophic heart.

Florian Thilo1, Ying Liu, Nico Schulz, Ulrich Gergs, Joachim Neumann, Christoph Loddenkemper, Maik Gollasch, Martin Tepel.   

Abstract

The aim of this study was to compare the expression of transient receptor potential vanilloid type 1 (TRPV1) channels in hypertrophic hearts from transgenic mice showing overexpression of the catalytic subunit alpha of protein phosphatase 2A alpha (PP2Ac alpha) with wild-type mice and with TRPV1-/- mice. Transcripts of TRPV1, matrix metalloproteinase 9 (MMP9), discoidin domain receptor family, member 2 (DDR-2), atrial natriuretic peptide (ANP), GATA 4, and regulatory microRNA (miR-21) were analyzed using quantitative real-time PCR. Ventricle-to-body-weight-ratio was significantly higher in PP2Ac alpha transgenic mice compared to wild-type mice and TRPV1-/- mice (8.6±1.3mg/g; 5.4±0.3mg/g; and 5.4±0.4mg/g; respectively; p<0.05 by Kruskal-Wallis test). TRPV1 transcripts were significantly higher in PP2Ac alpha transgenic mice compared to wild-type mice (1.7±0.2 arbitrary units vs. 0.8±0.1 arbitrary units; p<0.05). TRPV1 protein expression was also significantly higher in PP2Ac alpha transgenic mice compared to wild-type mice. A significant linear correlation was observed between TRPV1 transcripts and the ventricle-to-body-weight-ratio (Spearman r=0.78; p<0.05). The expression of DDR-2 was significantly higher in PP2Ac alpha transgenic mice compared to wild-type mice and TRPV1 knockout mice. The expression of miR21 was significantly higher in PP2Ac alpha transgenic mice compared with TRPV1-/- mice (0.103±0.018 (PP2Ac alpha transgenic mice); 0.089±0.009 (wild-type mice); and 0.045±0.013 (TRPV1-/- mice), respectively; p<0.05). Masson Goldner staining revealed that PP2Ac alpha transgenic mice showed increased heart fibrosis compared with TRPV1 knockout mice. The study suggests an important role of TRPV1 in the pathogenesis of genetically associated heart hypertrophy.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833132     DOI: 10.1016/j.bbrc.2010.09.017

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Mice lacking functional TRPV1 are protected from pressure overload cardiac hypertrophy.

Authors:  Cadie L Buckley; Alexander J Stokes
Journal:  Channels (Austin)       Date:  2011-07-01       Impact factor: 2.581

2.  Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure.

Authors:  Han-Jun Wang; Wei Wang; Kurtis G Cornish; George J Rozanski; Irving H Zucker
Journal:  Hypertension       Date:  2014-06-30       Impact factor: 10.190

3.  "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".

Authors:  Jaime S Horton; Takuya Shiraishi; Naghum Alfulaij; Andrea L Small-Howard; Helen C Turner; Tatsuki Kurokawa; Yasuo Mori; Alexander J Stokes
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

Review 4.  Does Transient Receptor Potential Vanilloid Type 1 Alleviate or Aggravate Pathological Myocardial Hypertrophy?

Authors:  Qiqi Yan; Jun Tang; Xin Zhang; Liuyang Wu; Yunyi Xu; Lihong Wang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

Review 5.  TRP Channels as Therapeutic Targets in Diabetes and Obesity.

Authors:  Andrea Zsombok; Andrei V Derbenev
Journal:  Pharmaceuticals (Basel)       Date:  2016-08-17

6.  Activation of transient receptor potential vanilloid 3 channel (TRPV3) aggravated pathological cardiac hypertrophy via calcineurin/NFATc3 pathway in rats.

Authors:  Qianhui Zhang; Hanping Qi; Yonggang Cao; Pilong Shi; Chao Song; Lina Ba; Yunping Chen; Jingquan Gao; Shuzhi Li; Baiyan Li; Hongli Sun
Journal:  J Cell Mol Med       Date:  2018-10-09       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.